Related Experiment Video

Updated: May 10, 2026

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

Canagliflozin for the treatment of type 2 diabetes

A Babu1

  • 1Department of Internal Medicine, Division of Endocrinology, John Stroger Hospital of Cook County, Chicago, Illinois, USA. ababu@cookcountyhhs.org

Drugs of Today (Barcelona, Spain : 1998)
|June 29, 2013
PubMed

Insights

Canagliflozin, a novel SGLT2 inhibitor, effectively lowers blood glucose in diabetes through insulin-independent action. While generally safe, careful patient selection and monitoring are crucial due to potential side effects.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Nephrology

Background:

  • Diabetes mellitus is a growing global health concern, often associated with obesity.
  • Current treatments have limitations, necessitating novel therapeutic approaches.
  • Sodium/glucose cotransporter 2 (SGLT2) inhibitors offer a unique, insulin-independent mechanism for glucose lowering.

Purpose of the Study:

  • To evaluate the efficacy and safety of canagliflozin, an oral SGLT2 inhibitor, for managing type 2 diabetes.
  • To assess its impact on glycemic control, weight, and potential side effects.

Main Methods:

  • Canagliflozin administration as an oral inhibitor of renal SGLT2.
  • Monitoring of blood glucose levels, HbA1c, weight changes, and incidence of hypoglycemia.
  • Assessment of safety profile, including urinary tract infections, genital infections, and blood pressure changes.

Main Results:

  • Canagliflozin effectively reduces HbA1c by 0.5 to 1.1% through glucosuria.
  • Promotes weight loss and has a low incidence of hypoglycemia.
  • Demonstrates safety in patients with compromised renal function, but requires monitoring for side effects like infections and hypotension.

Conclusions:

  • Canagliflozin represents a promising new oral SGLT2 inhibitor for diabetes treatment, particularly in the context of obesity.
  • Its insulin-independent action and complementary effects make it a valuable addition to antidiabetic therapies.
  • Careful patient selection and monitoring are essential to mitigate potential adverse events and optimize risk-benefit ratio.
Keywords:
CanagliflozinJNJ-28431754SGLT2Sodium/glucose cotransporter 2 inhibitorType 2 diabetes

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...